active surveillance from biology to bedside
Published 6 years ago • 2.5K plays • Length 26:28Download video MP4
Download video MP3
Similar videos
-
20:50
active surveillance 2021 - from bench to bedside
-
12:19
active surveillance 2022: who qualifies, who does not and how should it be monitored
-
23:37
active surveillance who is the right patient and what is the right protocol
-
1:58
integrated diagnostics and patient selection for active surveillance and treatment
-
11:13
active surveillance in favorable intermediate-risk prostate cancer
-
29:23
how should we monitor patients during surveillance?
-
24:04
active surveillance or focal therapy as primary management
-
25:24
active surveillance in 2021 part 2: imaging and biomarkers
-
34:00
active surveillance – when can you continue watching and when do you intervene?
-
6:09
germline testing for prostate cancer active surveillance
-
9:15
point-counterpoint: active surveillance for intermediate-risk prostate cancer - pro
-
20:39
active surveillance or: shrinking the gray zone
-
24:42
a radiation oncologist's approach to active surveillance and our role in local therapy
-
12:46
what role do markers play in establishing active surveillance or definitive care?
-
9:59
point-counterpoint: active surveillance for intermediate-risk prostate cancer - con
-
2:04
radiomics models for non-invasive identification of active surveillance candidates
-
2:04
active surveillance of renal mass
-
40:52
global grand rounds: active surveillance for prostate cancer with matthew e. nielsen, md, ms, facs
-
9:02
focal therapy for localized pca: is there a middle ground between active surveillance and treatment